Elbasvir
Chronic Hepatitis C Virus Infection
Explore 3 assets in Chronic Hepatitis C Virus Infection →Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Institute Of Cardiology & Internal Diseases, Kazakhstan
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03222167CT.gov Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b | — | Unknown | — | — | — |
NCT02973503CT.gov Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis | — | Completed | — | — | — |
NCT02115321CT.gov Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Elbasvir (this asset) | Institute Of Cardiology & Internal Diseases, Kazakhstan | P3 | BBB · 72 |
| Dasabuvir | AbbVie | P3 | A |
| Veruprevir | Ain Shams University | P3 | A |
| Ribavirin | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | P4 | A |
| Ombitasvir | Ain Shams University | P3 | A |
| Sofosbuvir | Peking University First Hospital | P4 | A |
| Pegyinterferon-Alfa-2A | Hoffmann-La Roche | P4 | A |
| Pibrentasvir | Kirby Institute | P3 | A |
| Glecaprevir | Kirby Institute | P3 | A |
+42 more in the Chronic Hepatitis C Virus Infection cohort
Other indications for Elbasvir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis C Virus Infection | — | P4 | BBB · 75 |
| Cirrhosis Of Liver | — | P4 | BBB · 72 |
| Hepatocellular Carcinoma | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Elbasvir in Chronic Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/elbasvir-chronic-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →